Weizmann Institute
Israeli Startup Curesponse Targets European Pharma Market With Drug Prediction, Development Service
Premium
The firm's technology uses ex vivo organ culture to model cancer growth and predict a patient's tumor response to chemotherapy and targeted drugs.
Israeli Startup Curesponse Raises $6M in Series A Financing
The Rehovot, Israel-based precision medicine firm will use the funding to scale clinical trials and expansion to the UK.
Study Finds Potential Biomarkers for Checkpoint Inhibitor Response in Melanoma
Overexpression of immunoproteasome components PSMB8 and PSMB9 were found to be predictive of improved survival and response to immunotherapy.